Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?. Issue 6 (24th March 2022)

• Record Type: Journal Article
• Authors: Laurie, Kathryn L.; Lee, Paul; Rademaker, Alfred; Alonzo, Todd A.; Wang, Yi‐Cheng; Powell, Bayard L.; Wu, Diana; Larson, Richard; Kutny, Matthew; Gregory, John; Hijiya, Nobuko; Feusner, James
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 6(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-24
• Subjects: acute promyelocytic leukemia -- obesity -- pediatric; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29613
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Objective: To compare outcomes of obese and nonobese pediatric patients with acute promyelocytic leukemia (APL) from the Cancer and Leukemia Group B trial (CALGB) 9710 and the Children's Oncology Group trial AAML0631. Methods: Data including demographics, adverse events, overall and event‐free survival (EFS) were analyzed. Results: The prevalence of obesity was 34% on C9710 and 35% on AAML0631. There was significantly lower overall and EFS in the obese population on multivariable analysis on AAML0631 but not on CALGB 9710. Eleven patients died during therapy or in follow‐up. Conclusion: The prevalence of obesity is higher in pediatric patients with APL compared to the general population. The decreased EFS and OS in obese patients on AAML0631 suggest that the presence of obesity can influence outcomes using the most current treatment. These findings support the need for further research on the potential role of obesity in pediatric APL leukemogenesis.